S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01
S&P 500   4,662.85
DOW   35,911.81
QQQ   380.01

Mainz Biomed B.V. Stock Forecast, Price & News

+4.43 (+26.95%)
(As of 01/14/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
592,100 shs
Average Volume
2.34 million shs
Market Capitalization
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive MYNZ News and Ratings via Email

Sign-up to receive the latest news and ratings for Mainz Biomed B.V. and its competitors with MarketBeat's FREE daily newsletter.

Mainz Biomed B.V. logo

About Mainz Biomed B.V.

Mainz Biomed N.V. develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company's flagship product is ColoAlert, an accurate, non-invasive, and easy-to-use early detection diagnostic test for colorectal cancer. Mainz Biomed N.V. is based in BERKELEY, Calif.


Why Mainz Biomed Shares Are Skyrocketing Today?
January 5, 2022 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales


Pretax Margin




Free Float
Not Optionable

Company Calendar

Fiscal Year End


Overall MarketRank

0.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Mainz Biomed B.V. (NASDAQ:MYNZ) Frequently Asked Questions

When did Mainz Biomed B.V. IPO?

(MYNZ) raised $10 million in an initial public offering on Friday, November 5th 2021. The company issued 2,000,000 shares at a price of $4.00-$6.00 per share. Boustead Securities served as the underwriter for the IPO.

What is Mainz Biomed B.V.'s stock symbol?

Mainz Biomed B.V. trades on the NASDAQ under the ticker symbol "MYNZ."

When did the company's quiet period expire?

Mainz Biomed B.V.'s quiet period expired on Wednesday, December 15th. Mainz Biomed B.V. had issued 2,000,000 shares in its initial public offering on November 5th. The total size of the offering was $10,000,000 based on an initial share price of $5.00. During the company's quiet period, insiders and any underwriters that worked on the IPO were restricted from issuing any research reports for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

How do I buy shares of Mainz Biomed B.V.?

Shares of MYNZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mainz Biomed B.V.'s stock price today?

One share of MYNZ stock can currently be purchased for approximately $20.87.

What is Mainz Biomed B.V.'s official website?

The official website for Mainz Biomed B.V. is mainzbiomed.com.

How can I contact Mainz Biomed B.V.?

The company can be reached via phone at 49-6131-554-2860 or via email at [email protected].

This page was last updated on 1/17/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.